In a society where neurological disorders represent a heavy burden, Philips is committed to provide superb diagnostic clarity and treatment guidance for all patients. Today, although MR is the gold standard in neuro oncology imaging, its accuracy in tumor grading and treatment follow up assessment can be further improved.
3D APT (Amide Proton Transfer) is a unique, contrast-free, brain MR imaging method addressing the need for more confident diagnosis in neuro oncology. 3D APT uses the presence of endogenous cellular proteins, to produce an MR signal that directly correlates with cell proliferation, a marker of tumoral activity. 3D APT can support trained medical professionals in differentiating low grade from high grade gliomas and, in differentiating tumor progression from treatment effect1.
Enhanced diagnostic confidence with 3D APT
3D T1w TFE3D APT
What our customers say about 3D APT
It would be impactful to have a sequence like APT, which could assist us in making those decisions with more confidence”
Jeffrey Miller, MD
Pediatric radiologist at Phoenix Children’s Hospital (PCH)
APT was added to about 70 MRI exams of children with brain tumor and we saw some encouraging early results”
1 Zhou et al., Nat Med 9, 1085-1090 (2003).; Zhou et al., Magn Reson Med 50, 1120-1126 (2003); Jones et al., Magn Reson Med 56, 585-592 (2006).
By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.